|
Age (years)
|
54.3 (46.0 to 64.1)
|
52.3 (45.1 to 61.5)
|
0.12
|
|
SSc duration by Raynaud's phenomenon (years)
|
6.4 (3.4 to 11.7)
|
7.0 (3.7 to 11.9)
|
0.21
|
|
SSc duration by first non-Raynaud's symptom (years)
|
5.4 (2.7 to 9.2)
|
6.0 (3.0 to 10.3)
|
0.20
|
|
Topoisomerase I (Scl70)-autoantibodiespositive
|
42.8
|
46.7
|
0.44
|
|
Anti-centromere autoantibodies-positive
|
14.9
|
15.7
|
0.82
|
|
U1RNP-positive
|
6.5
|
4.7
|
0.51
|
|
RNA polymerase III-positive
|
9.4
|
2.8
|
0.08
|
|
Diffuse SSc
|
56.8
|
63.7
|
0.18
|
|
Puffy hands
|
34.3
|
54.6
|
< 0.001*
|
|
mRSS
|
10 (4 to 16)
|
13 (6 to 20)
|
0.01*
|
|
mRSS > 20
|
16.8
|
25.0
|
0.05
|
|
C-reactive protein elevation
|
33.6
|
24.5
|
0.07
|
|
Digital ulcers
|
34.7
|
44.0
|
0.04*
|
|
Synovitis
|
13.1
|
20.0
|
0.05
|
|
Joint contractures
|
33.0
|
31.8
|
0.81
|
|
Tendon friction rubs
|
10.2
|
10.0
|
0.94
|
|
Muscle weakness
|
22.2
|
20.9
|
0.76
|
|
Muscle atrophy
|
11.1
|
15.5
|
0.17
|
|
Creatine kinase elevation
|
11.6
|
13.3
|
0.58
|
|
Oesophageal symptoms
|
54.4
|
60.4
|
0.23
|
|
Stomach symptoms
|
16.0
|
13.5
|
0.50
|
|
Intestinal symptoms
|
18.8
|
12.6
|
0.11
|
|
Lung fibrosis on chest X-ray or HRCT
|
60.4
|
56.7
|
0.59
|
|
Forced vital capacity (% predicted)
|
89 (75 to 101)
|
92 (81 to 103)
|
0.36
|
|
Forced vital capacity < 80%
|
32.2
|
23.3
|
0.10
|
|
DLCO (% predicted)
|
66 (49 to 82)
|
69 (55 to 88)
|
0.05
|
|
DLCO < 80%
|
71.
|
59.1
|
0.01*
|
|
PAPsys (mmHg)
|
30 (25 to 37)
|
27 (20 to 36)
|
0.004*
|
|
PAPsys > 40 mmHg
|
22.3
|
19.4
|
0.51
|
|
Diastolic dysfunction
|
20.4
|
18.8
|
0.70
|
|
Pericardial effusion
|
7.1
|
5.7
|
0.64
|
|
Left ventricular ejection fraction < 60%
|
25.1
|
20.0
|
0.31
|
|
Arterial hypertension
|
21.5
|
23.6
|
0.75
|
|
Renal crisis
|
3.3
|
4.5
|
0.50
|
|
Proteinuria
|
8.6
|
9.4
|
0.79
|
|
EULAR SSc activity score
|
1.5 (0.5 to 3.0)
|
2 (0.5 to 3.5)
|
0.27
|
|
High SSc activity (score ≥ 3)
|
27.2
|
35.2
|
0.19
|
|
Hypocomplementaemia
|
5.0
|
5.9
|
0.71
|
